A
21.60
2.48 (12.97%)
| Previous Close | 19.12 |
| Open | 21.97 |
| Volume | 120,045 |
| Avg. Volume (3M) | 113,901 |
| Market Cap | 1,882,941,184 |
| Price / Sales | 11.35 |
| Price / Book | 46.53 |
| 52 Weeks Range | |
| Earnings Date | 27 Mar 2025 |
| Profit Margin | -41.34% |
| Operating Margin (TTM) | -361.23% |
| Diluted EPS (TTM) | -0.730 |
| Quarterly Revenue Growth (YOY) | 97.90% |
| Total Debt/Equity (MRQ) | 608.58% |
| Current Ratio (MRQ) | 1.26 |
| Operating Cash Flow (TTM) | -111.36 M |
| Levered Free Cash Flow (TTM) | -81.25 M |
| Return on Assets (TTM) | -9.25% |
| Return on Equity (TTM) | -235.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ascentage Pharma Group Internat | - | - |
AIStockmoo Score
0.4
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |